Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial

Rini, Brian, I; Motzer, Robert J.; Powles, Thomas; McDermott, David F.; Escudier, Bernard; Donskov, Frede; Hawkins, Robert; Bracarda, Sergio; Bedke, Jens; De Giorgi, Ugo; Porta, Camillo; Ravaud, Alain; Parnis, Francis; Grande, Enrique; Zhang, Wei; Huseni, Mahrukh; Carroll, Susheela; Sufan, Roxana; Schiff, Christina; Atkins, Michael B.

Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial

Autor(en):

Rini, Brian, I; Motzer, Robert J.; Powles, Thomas; McDermott, David F.; Escudier, Bernard; Donskov, Frede; Hawkins, Robert; Bracarda, Sergio; Bedke, Jens; De Giorgi, Ugo; Porta, Camillo; Ravaud, Alain; Parnis, Francis; Grande, Enrique; Zhang, Wei; Huseni, Mahrukh; Carroll, Susheela; Sufan, Roxana; Schiff, Christina; Atkins, Michael B.

Tübinger Autor(en):

Bedke, Jens

Erschienen in:

European Urology (2021), Bd. 79, H. 5, S. 659-662

Verlagsangabe:

Elsevier

Sprache:

Englisch

Referenz zum Volltext:

http://dx.doi.org/10.1016/j.eururo.2020.06.021

ISSN:

1873-7560